192 related articles for article (PubMed ID: 19713220)
1. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.
Todoerti K; Barbui V; Pedrini O; Lionetti M; Fossati G; Mascagni P; Rambaldi A; Neri A; Introna M; Lombardi L; Golay J
Haematologica; 2010 Feb; 95(2):260-9. PubMed ID: 19713220
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
[TBL] [Abstract][Full Text] [Related]
3. ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.
Galimberti S; Canestraro M; Savli H; Palumbo GA; Tibullo D; Nagy B; Piaggi S; Guerrini F; Cine N; Metelli MR; Petrini M
Anticancer Res; 2010 Nov; 30(11):4525-35. PubMed ID: 21115902
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
Pichiorri F; Suh SS; Ladetto M; Kuehl M; Palumbo T; Drandi D; Taccioli C; Zanesi N; Alder H; Hagan JP; Munker R; Volinia S; Boccadoro M; Garzon R; Palumbo A; Aqeilan RI; Croce CM
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12885-90. PubMed ID: 18728182
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
6. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
Galli M; Salmoiraghi S; Golay J; Gozzini A; Crippa C; Pescosta N; Rambaldi A
Ann Hematol; 2010 Feb; 89(2):185-90. PubMed ID: 19633847
[TBL] [Abstract][Full Text] [Related]
7. Signal pathways, diseases, and functions associated with the miR-19a/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells.
Yin Z; Yang J; Ning R; Liu Y; Feng M; Gu C; Fei J; Li Y
J Biochem Mol Toxicol; 2018 Jun; 32(6):e22057. PubMed ID: 29687521
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
Zhang X; Chen Y; Zhao P; Zang L; Zhang Z; Wang X
Leuk Lymphoma; 2017 Apr; 58(4):932-940. PubMed ID: 27830963
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
Maharaj L; Marson CM; Middleton BJ; Rioja AS; Perry J; Oakervee H; Cavenagh J; Joel SP; Popat R
Br J Haematol; 2013 Oct; 163(1):135-9. PubMed ID: 23834265
[No Abstract] [Full Text] [Related]
10. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression of MicroRNA-19b Promotes Proliferation of Cancer Stem Cells by Regulating the TSC1/mTOR Signaling Pathway in Multiple Myeloma.
Wang N; Liang X; Yu W; Zhou S; Fang M
Cell Physiol Biochem; 2018; 50(5):1804-1814. PubMed ID: 30396185
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1β signaling in osteoarthritis fibroblast-like synoviocytes.
Wang JH; Shih KS; Wu YW; Wang AW; Yang CR
Osteoarthritis Cartilage; 2013 Dec; 21(12):1987-96. PubMed ID: 24107356
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
Humphreys KJ; Cobiac L; Le Leu RK; Van der Hoek MB; Michael MZ
Mol Carcinog; 2013 Jun; 52(6):459-74. PubMed ID: 22308110
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
Matalon S; Palmer BE; Nold MF; Furlan A; Kassu A; Fossati G; Mascagni P; Dinarello CA
J Acquir Immune Defic Syndr; 2010 May; 54(1):1-9. PubMed ID: 20300007
[TBL] [Abstract][Full Text] [Related]
18. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
19. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
20. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
